All In Biotech

Drug Trial Radar · NCT05158296

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Last checked: Nov 20, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

7

Actual

Start

Dec 8, 2021

Primary completion

Oct 12, 2022

Study completion Oct 12, 2022

Sponsor

Lead sponsor
Laboratoires TheaIndustry
Sponsor type
Industry
Collaborators
Sepul Bio
First posted
Dec 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.

Conditions

  • Retinitis Pigmentosa
  • Usher Syndrome Type 2
  • Deaf Blind
  • Retinal Disease
  • Eye Diseases
  • Eye Diseases, Hereditary
  • Eye Disorders Congenital
  • Vision Disorders

Interventions

  • UltevursenDrug

    RNA antisense oligonucleotide for intravitreal injection

  • Sham-procedureOther

    Sham-procedure (no experimental drug administered)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA)Time frame: 18 months of treatment versus sham-procedure

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Shiley Eye Institute - UC San Diego

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • University of Miami, Bascom Palmer Eye Institute

    Miami, Florida

  • Emory Eye Center

    Atlanta, Georgia

  • Wilmer Eye Institute, Johns Hopkins Hospital

    Baltimore, Maryland

  • Center for Clinical Research Operations, Massachusetts Eye and Ear

    Boston, Massachusetts

  • University of Michigan, Kellogg Eye Center

    Ann Arbor, Michigan

  • Columbia University

    New York, New York

  • Retina Foundation of the Southwest

    Dallas, Texas

  • University of Wisconsin - Madison

    Madison, Wisconsin

  • Universitaetsklinikum Tuebingen Department für Augenheilkunde

    Tübingen, Germany

  • RadboudUMC

    Nijmegen, Netherlands

  • Het Oogziekenhuis Rotterdam

    Rotterdam, Netherlands

  • Moorfields Eye Hospital

    London, United Kingdom

  • Oxford Eye Hospital

    Headington, Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.